Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

References

• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–10. doi:10.1158/2159-8290.CD-12-0548.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74. doi:10.1007/s12325-018-0805-y.
   PubMed Web of Science ®Google Scholar
• Pui CH, Yang JJ, Bhakta N, Rodriguez-Galindo C. Global efforts toward the cure of childhood acute lymphoblastic leukaemia [published correction appears in lancet child adolesc health]. Lancet Child Adolesc Health. 2018 Nov;2(6):440–54. doi:10.1016/S2352-4642(18)30066-X.
   PubMedGoogle Scholar
• Chang JH, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(Suppl S2):e28371. doi:10.1002/pbc.28371.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®): acute lymphoblastic leukemia. Version 1; 2024 [accessed 2024 Jun 4]. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf.
   Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma [published correction appears in blood adv]. Blood Adv. 2021 Feb 23 [2022 Mar 22];5(4):1731. doi:10.1182/bloodadvances.2020003092.
   Web of Science ®Google Scholar
• Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano J-A, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMed. 2023 [accessed 2023 Oct 26];65:102268. doi:10.1016/j.eclinm.2023.102268.
   PubMedGoogle Scholar
• Brissot E, Peczynski C, Labopin M, Lussana F, Hough R, Kuball J, Roesler W, Furst S, Barba P, Daskalakis M, et al. CD19 chimeric antigen receptor (CAR) T-Cell therapy for adults with B-Cell acute lymphoblastic leukemia (B-ALL): a large real-world series from acute leukemia working party of the European society for blood and marrow transplantation (EBMT) blood. Blood. 2022;140(Supplement 1):10389–90. doi:10.1182/blood-2022-158880.
   Google Scholar
• Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7(11):2436–48. doi:10.1182/bloodadvances.2022008981.
   PubMed Web of Science ®Google Scholar
• Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022;9(10):766–75. doi:10.1016/S2352-3026(22)00225-3.
   Web of Science ®Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021;398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8.
   PubMed Web of Science ®Google Scholar
• Bezerra E, Itani T, Wudhikarn K, Perales M-A, Yang Y, Gergis U, Aribi A, Hill LC, Jain N, Leonard JT, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry. Blood. 2023;142(Supplement 1):1029–1029. doi:10.1182/blood-2023-177693.
   PubMedGoogle Scholar
• Roloff G, Faramand R, Aldoss I, Kopmar NE, Schwartz M, Dekker SE, Lin C, Tracy S, Mercadal Vilchez S, Dykes K, et al. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-all. J Clin Oncol. 2023;41(16_suppl):7001–7001. doi:10.1200/jco.2023.41.16_suppl.7001.
   Web of Science ®Google Scholar
• Kurz KS, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H, Ott G, Staiger AM. Large B-Cell lymphomas in the 5th edition of the WHO-Classification of haematolymphoid neoplasms—updated classification and new concepts. Cancers (Basel). 2023 [accessed 2023 Apr 13];15(8):2285. doi:10.3390/cancers15082285.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathol. 2018;50(1):74–87. doi:10.1016/j.pathol.2017.09.006.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®): B-Cell lymphomas. Version 2; 2024 [accessed 2024 June 4]. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44. doi:10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–15. doi:10.1016/S1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020;396(10254):839–52. doi:10.1016/S0140-6736(20)31366-0.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–54. doi:10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial [published correction appears in lancet]. Lancet. 2022 Jul 16;400(10347):2294–308. doi:10.1016/S0140-6736(22)00662-6.
   Google Scholar
• Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transpl Cell Ther. 2024;30(1):77.1–5. doi:10.1016/j.jtct.2023.10.017.
   Google Scholar
• Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu Z-H, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl Cell Ther. 2022;28(9):581.1–8. doi:10.1016/j.jtct.2022.05.026.
   Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transpl Cell Ther. 2022;28(10):669–76. doi:10.1016/j.jtct.2022.07.011.
   PubMedGoogle Scholar
• Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–54. doi:10.1038/s41591-022-01969-y.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349–58. doi:10.1182/blood.2021015209.
   PubMed Web of Science ®Google Scholar
• Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Domínguez MLG, Pina JMS, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023 [accessed 2023 Jan 1];108(1):110–21. doi:10.3324/haematol.2022.280805.
   PubMed Web of Science ®Google Scholar
• Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O’Reilly M, et al. A national service for delivering CD19 CAR-T in large B-cell lymphoma – the UK real-world experience. Br J Haematol. 2022;198(3):492–502. doi:10.1111/bjh.18209.
   PubMed Web of Science ®Google Scholar
• Hess LM, Chen Y, Abada PB, Konig H, Walgren RA, Rice L. Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study. Adv Hematol. 2022 [accessed 2022 Dec 28];2022:1–8. doi:10.1155/2022/8262787.
   Google Scholar
• Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42. doi:10.1056/NEJMoa1914347.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–67. doi:10.1200/JCO.21.02370.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–606. doi:10.1200/JCO.22.01797.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: Elara trial update. Blood J. 2024 Jan 9];143(17):1713–25. doi:10.1182/blood.2023021567.
   PubMed Web of Science ®Google Scholar
• Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–10. doi:10.1182/bloodadvances.2021006922.
   PubMed Web of Science ®Google Scholar
• Herbaux C, Bret C, Di Blasi R, Bachy E, Beauvais D, Gat E, Gastinne T, Broussais F, Cartron G, Cuffel A, et al. KTE-X19 in relapsed or refractory mantle-cell lymphoma, a “real-life” study from the descar-T registry and Lysa group. Blood. 2021;138(Supplement 1):743–743. doi:10.1182/blood-2021-148626.
   PubMedGoogle Scholar
• O’Reilly MA, Sanderson R, Wilson W, Burns D, Besley C, Creasey T, Uttenthal B, Elliot J, Roddie C, Kuhnl A, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world outcomes in the United Kingdom. Blood. 2022;140(Supplement 1):7519–21. doi:10.1182/blood-2022-165031.
   Google Scholar
• Mohty R, Kharfan-Dabaja MA. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Ther Adv Hematol. 2022;13:13. doi:10.1177/20406207221142133.
   Web of Science ®Google Scholar
• Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–32. doi:10.1038/s41591-021-01622-0.
   PubMed Web of Science ®Google Scholar
• Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835–43. doi:10.1182/bloodadvances.2022008150.
   PubMed Web of Science ®Google Scholar
• Hao Y, Hsu WC, Parzynski CS, Degtyarev E, Hampson LV, Masood A, Wu WH. Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. J Comp Eff Res. 2023;12(7):e220173. doi:10.57264/cer-2022-0173.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. doi:10.1016/S1470-2045(21)00591-X.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496–506. doi:10.1182/blood.2023021243.
   PubMed Web of Science ®Google Scholar
• Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, et al. Comparative effectiveness of zuma-5 (axi-CEL) vs scholar-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–60. doi:10.1182/blood.2021014375.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Hemmer MT, Hu Z-H, Frank MJ, Popplewell L, Ahmed N, Lin Y, Best T, Beygi S, Miao HH, et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):7509–7509. doi:10.1200/jco.2023.41.16_suppl.7509.
   Web of Science ®Google Scholar
• Ysebaert L, Houot R, Casasnovas O, Sylvain C, Jardin F, Loschi M, Brisou G, Thieblemont C, Bay J-O, Castilla-Llorente C, et al. Real-world experience of car T-cells in patients with relapsed/refractory follicular lymphoma: a descart registry analysis from the lysa. Blood. 2023;142(Supplement 1):296–296. doi:10.1182/blood-2023-184653.
   Google Scholar
• Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021 [accessed 2021 Jan 20];9(1):3. doi:10.3390/medsci9010003.
   PubMedGoogle Scholar
• Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. doi:10.1056/NEJMoa2024850.
   PubMed Web of Science ®Google Scholar
• Anderson LD, Munshi NC, Shah N, Jagannath S, Berdeja JG, Lonial S, Raje NS, Siegel DSD, Lin Y, Oriol A, et al. Idecabtagene vicleucel (IDE-Cel, BB2121), a BCMA-directed car T-cell therapy, in relapsed and refractory multiple myeloma: updated KARMMA results. J Clin Oncol. 2021;39(15_suppl):8016–8016. doi:10.1200/jco.2021.39.15_suppl.8016.
   Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [published correction appears in lancet]. Lancet. 2021 Oct 2;398(10307):314–24. doi:10.1016/S0140-6736(21)00933-8.
   PubMed Web of Science ®Google Scholar
• Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Cost P, Schecter JM, Lendvai N, Patel N, Ishida T, et al. Comparative efficacy of ciltacabtagene autoleucel versus Idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison. Blood. 2023;142(Supplement 1):2141. doi:10.1182/blood-2023-182141.
   Google Scholar
• Sidana S, Ahmed N, Akhtar OS, Heim M, Brazauskas R, Hansen DK, Ferreri C, Freeman CLL, Afrough A, Anderson LD, et al. Real world outcomes with Idecabtagene vicleucel (IDE-CEL) CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood. 2023;142(Supplement 1):1027–1027. doi:10.1182/blood-2023-181762.
   Google Scholar
• Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR-T consortium. J Clin Oncol. 2023;41(11):2087–97. doi:10.1200/JCO.22.01365.
   PubMed Web of Science ®Google Scholar
• Dima D, Rashid A, Davis JA, Shune L, Abdallah A-O, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicentre study. Br J Haematol. 2024;204(4):1293–9. doi:10.1111/bjh.19302.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–14. doi:10.1056/NEJMoa2213614.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335–47. doi:10.1056/NEJMoa2303379.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®): multiple myeloma. Version 4. 2024 [accessed 2024 June 4]. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
   Google Scholar
• Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495. doi:10.3389/fimmu.2023.1101495.
   PubMed Web of Science ®Google Scholar
• Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic lymphocytic leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Mar 7. https://www.ncbi.nlm.nih.gov/books/NBK470433/.
   Google Scholar
• Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. The Lancet. 2023;402(10402):641–54. doi:10.1016/S0140-6736(23)01052-8.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Commissioner O of the FDA roundup; 2024 Jan 23 [accessed 2024 Apr 10]. https://www.fda.gov/news-events/press-announcements/fda-roundup-january-23-2024.
   Google Scholar
• Verdun N, Marks P. Secondary cancers after chimeric antigen receptor t-cell therapy. N Engl J Med. 2024;390(7):584–6. doi:10.1056/NEJMp2400209.
   PubMedGoogle Scholar